Bliss GVS Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Bliss GVS Pharma Ltd reported a 13.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 27.7%.
• Its expenses for the quarter were up by 15.5% QoQ and 19.6% YoY.
• The net profit increased 49.3% QoQ and increased 122.2% YoY.
• The earnings per share (EPS) of Bliss GVS Pharma Ltd stood at 3.28 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bliss GVS Pharma Ltd is a pharmaceutical company engaged primarily in the production and marketing of pharmaceutical formulations. The company operates in the healthcare industry, focusing on various therapeutic categories such as gynecology, antimalarials, and antibiotics. As of the data available up to October 2023, there is no specific information regarding recent major developments or significant events involving Bliss GVS Pharma Ltd. The company's operations are generally aligned with the pharmaceutical sector's standards and practices, aiming to provide quality healthcare solutions.

Revenue

During the fourth quarter of the fiscal year 2026, Bliss GVS Pharma Ltd reported a total income of ₹268.15 crores. This represents a quarter-over-quarter (QoQ) increase of 13.3% from ₹236.71 crores in Q3FY26. The year-over-year (YoY) growth is notable at 27.7%, up from ₹210.05 crores in Q4FY25. The increase in total income highlights a positive trajectory over both the quarterly and annual periods. The data indicates steady revenue growth, which is crucial for maintaining operational stability and supporting further business initiatives.

Profitability

In the fourth quarter of FY26, Bliss GVS Pharma Ltd achieved a profit before tax of ₹44.95 crores, reflecting a 9.9% QoQ increase from ₹40.90 crores in the previous quarter. Compared to the same quarter in the previous fiscal year (Q4FY25), profitability surged by 91.8% from ₹23.44 crores. The company's tax expenses for Q4FY26 were significantly reduced by 50.7% QoQ to ₹7.95 crores, contributing to a profit after tax of ₹37.00 crores. This result marks a 49.3% increase from the preceding quarter and a substantial 122.2% rise from the corresponding quarter last year, where the profit after tax was ₹16.65 crores. These figures underline the company's enhanced profitability over both the recent quarter and the past year.

Operating Metrics

The earnings per share (EPS) for Bliss GVS Pharma Ltd in Q4FY26 was reported at ₹3.28, demonstrating a QoQ growth of 53.3% compared to ₹2.14 in Q3FY26. The YoY increase in EPS is even more pronounced at 124.7%, up from ₹1.46 in Q4FY25. This improvement in EPS reflects the company's capacity to generate higher earnings for its shareholders over both the quarterly and annual periods. The company's total expenses in Q4FY26 were ₹223.23 crores, showing a 15.5% increase from the previous quarter and a 19.6% rise from the same quarter in the prior year. Despite the increase in expenses, the substantial growth in revenue and profitability metrics suggests effective cost management and operational efficiency.